Ushakiran Finance is a non-banking financial company that primarily manages a portfolio of equity and mutual fund investments while providing small-scale unsecured loans to various entities.
The company lacks a competitive advantage, as evidenced by extremely low returns on capital (avg ROCE 2.7%) and a business model that essentially functions as a small, high-cost closed-end investment vehicle with no proprietary deal flow or scale benefits.
Capital is primarily deployed into a fragmented portfolio of listed equities and mutual funds rather than growing a core lending business; the lack of dividends despite high net margins suggests a preference for retaining capital in a low-return environment.
Five years out, the company has withered into a stagnant pool of capital as its concentrated bet on Sigachi Industries soured and the loan book, already plagued by a 30% delinquency rate, finally collapsed under the weight of uncollectible 'on-demand' receivables. Management's refusal to return capital despite anemic returns led to a slow bleed of book value, while the lack of a core operating engine meant there was no cash flow to offset investment losses. The entity effectively functioned as a poorly managed closed-end fund that the market eventually priced at a massive discount to its dwindling net asset value.
RichFakir rates Ushakiran Finance Ltd's business quality as poor — 25/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Ushakiran Finance Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Ushakiran Finance Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Ushakiran Finance Ltd's fair value is about ₹4 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →